Uveitis

Sirolimus shows promise for posterior segment non-infectious uveitisIntravitreal sirolimus 400 mcg (Ospiria, Santen) demonstrated positive results in pivotal trials investigating it as a treatment for non-infectious uveitis of the posterior segment. A New Drug Application is under FDA review.
New and different therapies emerging through uveitis pipelineLocal therapy plays a significant role in the treatment of uveitis, either as monotherapy or in combination therapy. Alongside a number of pharmacotherapeutic agents, new products and technologies are in development that could expand clinicians’ options and improve outcomes.
Researchers find arthritis therapy ‘effective’ for noninfectious uveitisMultiple intravenous administrations of tocilizumab for noninfectious uveitis can be effective in improving visual acuity and reducing vitreous haze.
Portable imaging system captures quality images
Portable imaging system captures quality imagesNew technology has been paired with the time-tested technique of direct ophthalmoscopy to create a portable, retinal imaging system (D-Eye, D-Eye S.r.l.) that utilizes a small optical device magnetically attached to a smartphone
Multimodal imaging approach useful in treatment of uveitisSuccessful imaging for the group of diseases known as uveitis depends on the specific underlying etiology. Tailoring the imaging approach using a variety of imaging methods, which are often complementary, can yield the maximum amount of information. This approach is useful not only for diagnosis and management of patients, but increasingly in clinical trials.
SAKURA program reinforces efficacy, safety of intravitreal sirolimusResults from the Study Assessing double-masKed Uveitis tREAtrement (SAKURA) program support the efficacy and safety of intravitreal sirolimus 440 mcg (Opsiria, Santen) for treating noninfectious uveitis of the posterior segment, said Pauline T. Merrill, MD.
Adalimumab promising in treating JIA-associated uveitis, study findsResults from the Study Assessing double-masKed Uveitis tREAtrement (SAKURA) program support the efficacy and safety of intravitreal sirolimus 440 mcg (Opsiria, Santen) for treating noninfectious uveitis of the posterior segment, said Pauline T. Merrill, MD.
var script= ' ';